Ethosuximide (All indications) updated on 04-22-2025

Microcephaly / Small head circumference for gestational age

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16077
R66719		 Christensen (Ethosuximide) (All indications) (Controls exposed to LTG), 2024 Microcephaly (z-score for head circumference ≤3rd percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.47 [0.09;25.17] C
excluded (control group) 		0/11   274/8,756 274 11
ref
S16061
R66656		 Christensen (Ethosuximide) (All indications) (Controls unexposed, general population), 2024 Microcephaly (z-score for head circumference ≤3rd percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: No 1.54 [0.09;26.28] C 0/11   134,023/4,467,848 134,023 11
ref
Total 1 studies 1.54 [0.09;26.28] 134,023 11
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Ethosuximide) (All indications) (Controls unexposed, general population), 2024Christensen, 2024 1 1.54[0.09; 26.28]134,023110%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Ethosuximide) (All indications) (Controls unexposed, general population;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.54[0.09; 26.28]134,02311 -NAChristensen (Ethosuximide) (All indications) (Controls unexposed, general population), 2024 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.54[0.09; 26.28]134,02311 -NAChristensen (Ethosuximide) (All indications) (Controls unexposed, general population), 2024 1 Tags Adjustment   - No  - No 1.54[0.09; 26.28]134,02311 -NAChristensen (Ethosuximide) (All indications) (Controls unexposed, general population), 2024 1 All studiesAll studies 1.54[0.09; 26.28]134,02311 -NAChristensen (Ethosuximide) (All indications) (Controls unexposed, general population), 2024 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 16077

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.54[0.09; 26.28]134,02311 -NAChristensen (Ethosuximide) (All indications) (Controls unexposed, general population), 2024 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.47[0.09; 25.17]27411 -NAChristensen (Ethosuximide) (All indications) (Controls exposed to LTG), 2024 10.510.01.0